Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 61 results for "astrazeneca"

AstraZeneca Pharma, Nitta Gelatin down 4-9% on poor Q4 numbers
Money Control

Bitter pill for AstraZeneca Pharma after reverse turnaround in Q4

AstraZeneca Pharma India lost 3.2% to Rs 960 at 13:21 IST on BSE after the company reported net loss of Rs 2.88 crore in Q4 March 2017, compared with net profit of Rs 0.56 crore in Q4 March 2016. Business Standard, 2 weeks ago

404 images for astrazeneca

Reuters, 2 days ago
Reuters, 1 week ago
Reuters, 1 week ago
Reuters, 1 week ago
Money Control, 2 weeks ago
Money Control, 2 weeks ago
Reuters, 2 weeks ago
Reuters, 3 weeks ago
DNA, 2 weeks ago
Reuters, 4 weeks ago

AstraZeneca immunotherapy wins first approval in bladder cancer

⇒ Bladder cancer marks first approval for AZ's durvalumab ⇒ Big market is in lung cancer, where data due mid-year ⇒‚Äč AstraZeneca sets durvalumab price at $15,000/month US regulators have approved AstraZeneca's key immunotherapy drug ...
 DNA3 weeks ago FDA approves AstraZeneca's immunotherapy for bladder cancer  Reuters3 weeks ago Chinese drug approval boosts AstraZeneca's lung cancer hopes  Reuters1 month ago

SGLT-2 medicines reduce risk of heart failure: AstraZeneca

More than 300,000 patients with type-2 diabetes who were treated with SGLT-2 inhibitors, showed that all-cause mortality was reduced by 51 per cent and risk of hospitalisation for heart failure by 39 per cent, a study has revealed.
 DNA2 months ago

As AstraZeneca chases rivals, immuno-oncology gets complicated

Three years after Pfizer's failed bid for AstraZeneca, the British drugmaker aims to prove in the coming weeks that its cancer immunotherapy can deliver on bold sales forecasts made during that takeover battle. Central to AstraZeneca's case is a trial called ...
 Reuters1 month ago

How AstraZeneca cancer drug forecasts are set to rise

Sales forecasts for AstraZeneca's all-important new cancer immunotherapy drug Imfinzi are set to rise after the drugmaker received an unexpectedly early boost for the medicine in lung cancer last week. [nL8N1IE19S] Consensus sales forecast compiled before ...
 Reuters1 week ago Key AstraZeneca drug shown to reduce risk of death from lung cancer  DNA1 week ago AstraZeneca shares surge after key drug shows promise in lung cancer trial  Reuters1 week ago AstraZeneca third-line lung cancer trial delayed by few months  Reuters4 weeks ago

AstraZeneca asthma shot hits goal but diabetes drug lags rival

LONDON (Reuters) - AstraZeneca's experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroid drugs in a late-stage study, boosting hopes for a medicine that is expected to reach the market later this year.
 Reuters3 days ago AstraZeneca's asthama drug fails in study  DNA2 weeks ago AstraZeneca asthma drug fails, after similar setback at Roche  Reuters2 weeks ago Drug spun off by AstraZeneca shows promise in hot flashes  Reuters1 month ago

AstraZeneca boosts early respiratory medicine with Pieris deal

AstraZeneca boosted its early-stage respiratory medicine pipeline on Wednesday by signing a deal with Pieris Pharmaceuticals to develop novel inhaled drugs that could fight asthma in new ways. Pieris will get upfront and near-term milestone payments of $57.5 ...
 Reuters3 weeks ago

Circassia strikes deal with AstraZeneca for respiratory drugs

Britain's Circassia has secured the U.S. rights from AstraZeneca for two drugs to treat chronic obstructive pulmonary disease (COPD), a progressive lung condition affecting millions of people, for up to $230 million. Shares in Circassia jumped as much as 30 ...
 Reuters2 months ago

Drug approvals bounce back as R&D labs churn out new winners

By Ben Hirschler LONDON (Reuters) - The number of new drugs approved for sale in United States and Europe has bounced back this year, suggesting a marked slowdown in 2016 was an aberration rather than a sign of flagging research and development productivity.
 Sify18 hours ago

UK Stocks-Factors to watch on May 23

May 23 (Reuters) - Britain's FTSE 100 index is seen opening up 9points at 7505 on Tuesday, according to financial bookmakers. * At least 19 people were killed and 59 wounded in an explosion at the endof a concert by U.S. singer Ariana Grande in the English ...
 Sify3 days ago UPDATE 1-UK Stocks-Factors to watch on May 23  Sify3 days ago UK Stocks-Factors to watch on May 15  Sify1 week ago UK Stocks-Factors to watch on March 20  Sify2 months ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less